<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03855423</url>
  </required_header>
  <id_info>
    <org_study_id>853.4</org_study_id>
    <nct_id>NCT03855423</nct_id>
  </id_info>
  <brief_title>Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women With Breast Cancer</brief_title>
  <acronym>Matriac</acronym>
  <official_title>Malaysian Tocotrienol Rich Fraction: Immunomodulatory Effect in Women With Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nur Aishah Mohd Taib</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Malaysia Palm Oil Board</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Malaya</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase Ib: Maximum Tolerated Dose, Safety and Pharmacologic Study of TRF in Women with Breast
      Cancer is aimed to determine the highest, safest and tolerable dose of Tocotrienol-rich
      Fraction (maximal tolerated dose: MTD) that can be used in women with breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      3+3 step up design method will be used in this study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 18, 2019</start_date>
  <completion_date type="Anticipated">December 31, 2019</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <intervention_model_description>Single arm intervention study 3+3 step up design</intervention_model_description>
    <primary_purpose>Other</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Physical Assessment</measure>
    <time_frame>For 2 to 4 weeks during supplementation</time_frame>
    <description>Number of participants with treatment-related adverse events as assessed by CTCAE version 5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Liver Function Test</measure>
    <time_frame>For 2 to 4 weeks during supplementation</time_frame>
    <description>Liver enzymes with units of U/L</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Bioavailability of TRF</measure>
    <time_frame>For 2 to 4 weeks during supplementation</time_frame>
    <description>Blood pharmacokinetic parameters</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">12</enrollment>
  <condition>Breast Cancer Female</condition>
  <arm_group>
    <arm_group_label>Tocotrienol-rich Fraction (TRF)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pre-operative patients will be receiving TRF at different doses assigned to them in a cohort of 3 patients at each level.</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>Tocotrienol-rich Fraction (TRF)</intervention_name>
    <description>TRF consists of alpha, gamma and delta tocotrienols in addition to small amount of alpha-tocopherol</description>
    <arm_group_label>Tocotrienol-rich Fraction (TRF)</arm_group_label>
    <other_name>Tocovid Suprabio</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with operable breast cancer

          -  Life expectancy of at least 3 months

          -  Adequate organ function

          -  No allergy to Vitamin E and TRF

          -  Provides consent to participate in trial and adhere to the study protocol

        Exclusion Criteria:

          -  Receiving concomitant chemotherapy, radiotherapy, hormonal, immune therapy or other
             investigational drugs

          -  Uncontrolled concurrent illness

          -  Pregnant / breast feeding women

          -  Patients who are unable or unwilling to take Tocotrienols, herbal remedies, or
             non-prescription medications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Nur Aishah Taib, MBBS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Malaya</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Nur Aishah Taib, MBBS</last_name>
    <phone>+60379493642</phone>
    <email>nuraish@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Malaya Medical Center</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nur Aishah Taib, MBBS</last_name>
    </contact>
  </location>
  <location_countries>
    <country>Malaysia</country>
  </location_countries>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>February 14, 2019</study_first_submitted>
  <study_first_submitted_qc>February 25, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">February 26, 2019</study_first_posted>
  <last_update_submitted>April 18, 2019</last_update_submitted>
  <last_update_submitted_qc>April 18, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 19, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>University of Malaya</investigator_affiliation>
    <investigator_full_name>Nur Aishah Mohd Taib</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>MTD</keyword>
  <keyword>TRF</keyword>
  <keyword>Pharmacology</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tocotrienols</mesh_term>
    <mesh_term>Vitamin E</mesh_term>
    <mesh_term>Tocopherols</mesh_term>
    <mesh_term>Tocovid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

